Abbott Serlect NDA withdrawn; Lundbeck U.K. cohort study focusing on arrhythmias.
Executive Summary
ABBOTT SERLECT STUDY PLANS UNDECIDED AFTER NDA WITHDRAWAL Jan. 13, the company said. Abbott has said that it is conducting clinical trials examining the antipsychotic Serlect (sertindole) in patients failing risperidone (Janssen's Risperdal) and an open-label extension of trial M94-222. A study in Alzheimer's disease patients was planned in 1996. The Danish firm H. Lundbeck, which licenses sertindole to Abbott for the U.S., Canada, and Latin American territories, continues to market the drug as Serdolect in 12 European countries.